Protalix BioTherapeutics, Inc.

PLX is the ticker symbol for Protalix BioTherapeutics, Inc., a publicly traded US company.

Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.

Key metrics include a return on equity of 27.3%, a debt-to-equity ratio of 0.52.

The company reports trailing twelve-month revenue of $33.75M and net income of $18.32M.

FINOTAUR aggregates real-time and fundamental data on PLX to help traders and investors make informed decisions. Track PLX in your trading journal alongside other positions for a unified view of your portfolio.